205076: A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblind), Placebo- Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Severe, Poorly Controlled Asthma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Sirukumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Aug 2017 Status changed from suspended to withdrawn prior to enrolment.
- 26 Aug 2017 Trial has been Discontinued in Spain.
- 10 Jun 2017 Biomarkers information updated